Addus HomeCare Corp (ADUS) FY2025 10-K Annual Report

Filed: Feb 24, 2026
Health Care
Services-Home Health Care ServicesSEC EDGAR

Addus HomeCare Corp (ADUS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.

Addus HomeCare Corp FY2025 10-K Analysis

Business Overview

  • Core business: Home-based care services including personal care, hospice, and home health primarily for dual-eligible Medicare and Medicaid consumers
  • New emphasis: Expansion of clinical care services and full integration of personal care, hospice, and home health in Ohio, Tennessee, Illinois, and New Mexico
+3 more insights

Management Discussion & Analysis

  • Revenue $1.423B in 2025, up 23.2% YoY from $1.155B in 2024; personal care +$232.6M, hospice +$34.4M, home health +$0.9M
  • Operating margin 9.7% in 2025 vs 8.9% in 2024; gross margin steady at 32.5% both years
+6 more insights

Risk Factors

  • Variable interest rates on $124.3 million revolving loan with $8.5 million interest payable within 12 months at 5.48% as of January 2026
  • Inflation-driven wage increases impacting caregiver labor costs amid tight labor market and limited fee rate increases from government programs
+1 more insights

Addus HomeCare Corp FY2025 Key Financial Metrics
XBRL

Revenue

$1.4B

+23.2% YoY

Net Income

$96M

+30.3% YoY

Gross Margin

32.5%

-1bp YoY

Operating Margin

9.7%

+85bp YoY

Net Margin

6.7%

+37bp YoY

ROE

8.8%

+125bp YoY

Total Assets

$1.4B

+1.7% YoY

EPS (Diluted)

$5.22

+23.4% YoY

Operating Cash Flow

$112M

-4.2% YoY

Source: XBRL data from Addus HomeCare Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Addus HomeCare Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.